Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
P 1 (3)

Trial Status

Unknown3

Clinical Trials (3)

Showing 3 of 3 trials
NCT02822066Phase 1UnknownPrimary

Effectivity and Safety of Irreversible Electroporation for Refractory Neoplasms in Liver and Pancreas

NCT02822053Phase 1UnknownPrimary

Effectivity and Safety of Ultrasound-guided Percutaneously Laser Ablation for Refractory Neoplasms

NCT02816944Phase 1UnknownPrimary

Effectivity and Safety of Endoscopic Ultrasonography-guided Laser Ablation for Refractory Neoplasms

Showing all 3 trials

Research Network

Activity Timeline